Amazon Great Indian Festival 2020 - Electronics
Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Amazon Great Indian Festival 2020 - Electronics
Research

| More

Dr. Reddy's Laboratories - Settles Revlimid litigation in US - ICICI Securities

Posted On: 2020-09-18 01:47:48


Dr. Reddy's Laboratories' (DRL) announced settlement of Revlimid (lenalidomide) patent litigation in US with innovator Celgene (subsidiary of Bristol Myers Squibb). As per the settlement, Celgene would provide DRL with a license to sell generic Revlimid from a date after Mar'22 (post Natco's launch) with a constraint of volume market share. This license agreement would continue until Jan'26, post which DRL would be able to sell without any constraint. This development rovides certainty to launch and a material earnings accretion over FY23-FY26. We estimate DRL to generate cumulative sales and PAT of US$2.5bn and US$1.6bn respectively over this shared exclusivity period. We value this opportunity at Rs514/share for DRL considering annual market size of US$8bn and gradual market share increase to 18% in FY26. Maintain ADD.

- Settlement brings launch certainty: DRL has settled ongoing patent litigation with Celgene over Revlimid launch in US. It would now be able to launch post Natco which has a launch date in Mar'22. DRL would be bound by market share constraints as per agreement and we expect it to start with low single digit market share in the first year. This would gradually increase over the years and we expect ~18% share in final year (FY26E). Exact launch date and market share details have not been disclosed. Revlimid is indicated for treatment of multiple myeloma and myelodysplastic syndromes.

- It's a large opportunity: Revlimid generated over US$4bn sales for Celgene in first half of 2020 hence, we assume annual market size of US$8bn in US. We believe DRL would launch ~6months after Natco, that is in Oct'22. We value this opportunity at Rs514/share for DRL.

- Valuations and risks: We raise FY23 revenue/EPS estimates by 7.8/38.0% to factor in Revlimid launch. We maintain ADD rating with revised target price of Rs5,214/share (earlier: Rs4,713) based on 25xSep'22E base business EPS and Rs514/share for Revlimid. Key downside risks: Delay in launch of key products in US and regulatory hurdles.

Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.4826.6 as compared to the previous close of Rs. 4631.55. The total number of shares traded during the day was 307270 in over 24238 trades.

The stock hit an intraday high of Rs. 4845 and intraday low of 4657.2. The net turnover during the day was Rs. 1462805209.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com

Amazon Great Indian Festival 2020 - Mobiles


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Nestle India - 3QCY20 results - First Cut - YES SECURITIES

Crude Oil - Oct 23, 2020 - Reliance Securities

Maintain BUY on Ambuja Cements - Stellar show yet again; dividend bonanza announced - HDFC Securities

ADD on Bajaj Auto - Margin beat - HDFC Securities

Maintain REDUCE on Asian Paints - Standing tall - HDFC Securities

SBI cards - Q2FY21 - Angel Broking

Biocon - Q2FY21 - Angel Broking

Mphasis - Q2FY21 numbers - Angel Broking

L&T Finance Holdings - Q2FY21 - Angel Broking

HDFC AMC - Q2FY21 - Angel Broking

Bajaj Finserv (Not rated) - Q2 FY21 Conference Call Takeaways - YES Securities

Syngene International - Q2FY21 conference call takeaways - YES Securities

SBI Cards Q2FY21 Call Highlights - YES Securities

Sterlite Technologies (Q2FY21) - Conference call takeaways - YES Securities

Asian Paints Ltd - Q2FY21 Result Update - YES Securities

HDFC AMC - Q2FY21 Result Update - YES Securities

Alembic Pharma - Solid delivery continues; Top pick BUY TP Rs 1,180 - YES Securities

Sterlite Technologies - Q2FY21 First Cut - ICICI Securities

Tata Metaliks - Q2FY21 Company Update - ICICI Securities

Bajaj Auto - Q2FY21 First Cut - ICICI Securities

Bajaj Finserv - Q2FY21 Result Update - ICICI Securities

Asian Paints - Q2FY21 First Cut - ICICI Securities

Bharti Infratel - Q2FY21 - Angel Broking

Asian Paints - Q2FY21 - Angel Broking

Bajaj Auto - Q2FY21 numbers - Angel Broking

Maintain ADD on Bajaj Finance - Prudent provisioning hits profits - HDFC Securities

FDA warning letter to Aurobindo Pharma - Angel Broking

Chennai Petroleum - Q2FY221 Results - Angel Broking

Maintain ADD on Colgate Palmolive - Healthy domestic recovery; robust margin show - HDFC Securities

Maintain BUY on UltraTech Cement - Well-rounded performance - HDFC Securities

DB Corp - Q2FY21 Result Update - ICICI Securities

Bajaj Finance - Q2FY21 Result Update - ICICI Securities

Colgate-Palmolive (India) - Q2FY21 Result Update - ICICI Securities

UltraTech Cement - Q2FY21 Result Update - ICICI Securities

Larsen & Toubro Infotech - Q2FY21 Result Update - ICICI Securities

Sagar Cements - Q2FY21 First Cut - ICICI Securities

JK Tyre & Industries - Q2FY21 First Cut - ICICI Securities

Bajaj Finserv - Q2FY21 First Cut - ICICI Securities

UltraTech Q2FY21 - Retain ADD with TP of Rs 5,104 - YES Securities

Bajaj Finance - Q2FY21 - Result Update - YES Securities

Sagar Cements Q2FY21 - EBITDA at lifetime high; maintain TP of Rs 745 - YES Securities

JK Tyre - Q2FY2021 numbers - Angel Broking

Sagar Cements - Q2FY21 Results - Angel Broking

Bajaj Finance - Q2FY21 Results - Angel Broking

Bajaj Finance Q2FY21 - Retain ADD - 12m PT of Rs. 3,600 - YES SECURITIES

PNC Infratech - JV emerges L1 bidder - Angel Broking

GMM Pfaudler - Q2FY21 Results - Angel Broking

Rane Madras - Q2FY21 numbers - Angel Broking

Colgate-Palmolive - Q2FY21 Result - Angel Broking

Quant Pick - Tata Steel - ICICI Securities







Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2019